medigraphic.com
ISSN 0210-5187 (Digital)

2004, Número 5

<< Anterior Siguiente >>

Med Cutan Iber Lat Am 2004; 32 (5)


Una visión de los linfomas cutáneos primarios de células B

García HA, Estrach PT

Idioma: Español
Referencias bibliográficas: 136
Paginas: -198
Archivo PDF: 806.61 Kb.


RESUMEN

Los linfomas cutáneos primarios de células B (LCPCB) forman parte del grupo de linfomas no Hodgkin y representan un grupo heterogéneo de neoplasias con un tropismo especial por la piel. La etiopatogenia y el curso clínico de estos linfomas difieren de lo descrito para las neoplasias nodales correspondientes desde el punto de vista morfológico, y esto ha justificado la clasificación órgano-específica propuesta por la EORTC. Sin embargo, la falta de consenso con los criterios diagnósticos para las diferentes entidades que componen el grupo de los LCPCB ha supuesto que su clasificación sea un tema de continuo debate y base de las discrepancias en la terminología empleada entre anatomopatólogos, hematólogos, oncólogos y dermatólogos.A pesar del excelente pronóstico que presentan la mayoría de estos linfomas, las recidivas ocurren en un 30 a 60% de los casos, lo que hace indispensable un protocolo de seguimiento periódico y pautas de tratamiento acordes con la historia natural de estas neoplasias, estos aspectos se describen en el presente artículo.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Willemze R, Kerl H, Sterry W, Berti E, et al. EORTC classification for primary cutaneous lymphomas: a proposal from the Cutaneous Lymphoma Study Group of the European Organization for Research and Treatment of Cancer. Blood 1997; 90: 354-71.

  2. Prince HM, Yap LM, Blum R, McCormack C. Primary cutaneous B-cell lymphomas. Clin Exp Dermatol 2003; 28: 8-12.

  3. Yang B, Tubbs RR, Finn W, Carlson A, et al. Clinicopathologic reassessment of primary cutaneous B-cell lymphomas with immunophenotypic and molecular genetic characterization. Am J Surg Pathol 2000; 24: 694-702.

  4. Pandolfino TL, Siegel RS, Kuzel TM, Rosen ST, et al. Primary cutaneous B-cell lymphoma: review and current concepts. J Clin Oncol 2000; 18: 2152-68.

  5. Norton AJ. Classification of cutaneous lymphoma: a critical appraisal of recent proposals. Am J Dermatopathol 1999; 21: 279-87.

  6. Duncan LM. Cutaneous lymphoma. Understanding the new classification schemes. Dermatol Clin 1999; 17: 569-92.

  7. Willemze R, Meijer CJ. EORTC classification for primary cutaneous lymphomas: the best guide to good clinical management. European Organization for Research and Treatment of Cancer. Am J Dermatopathol 1999; 21: 265-73.

  8. Braun-Falco O, Burg G, Schmoeckel C. Recent advances in the understanding of cutaneous lymphoma. Clin Exp Dermatol 1981, 6: 89-109.

  9. Knowles DM, Halper JP, Jakobiec FA. The immunologic characterization of 40 extranodal lymphoid infiltrates: usefulness in distinguishing between benign pseudolymphoma and malignant lymphoma. Cancer 1982; 49: 2321-35.

  10. Wood GS, Burke JS, Horning S, Doggett RS, et al. The immunologic and clinicopathologic heterogeneity of cutaneous lymphomas other than mycosis fungoides. Blood 1983; 62: 464-72.

  11. Pimpinelli N, Santucci M, Bosi A, Moretti S, et al. Primary cutaneous follicular centre-cell lymphoma--a lymphoproliferative disease with favourable prognosis. Clin Exp Dermatol 1989; 14: 12-9.

  12. Burg G, Kaudewitz P, Klepzig K, Przybilla B, et al. Cutaneous B-cell lymphoma. Dermatol Clin 1985; 3: 689-704.

  13. Sander CA, Kind P, Kaudewitz P, Raffeld M, et al. The Revised European-American Classification of Lymphoid Neoplasms (REAL): a new perspective for the classification of cutaneous lymphomas. J Cutan Pathol 1997; 24: 329-41.

  14. Willemze R, Meijer CJ. EORTC classification for primary cutaneous lymphomas: the best guide to good clinical management. European Organization for Research and Treatment of Cancer. Am J Dermatopathol 1999; 21: 265-73.

  15. Russell-Jones R. Primary cutaneous B-cell lymphoma: how useful is the new European Organization for Research and Treatment of Cancer (EORTC) classification? Br J Dermatol 1998; 139: 945-9.

  16. Russell-Jones R. World Health Organization classification of hematopoietic and lymphoid tissues: implications for dermatology. J Am Acad Dermatol 2003; 48: 93-102.

  17. Kerl H, Cerroni L. Controversies in cutaneous lymphomas. Semin Cutan Med Surg 2000; 19: 157-60.

  18. Fink-Puches R, Zenahlik P, Back B, Smolle J, et al. Primary cutaneous lymphomas: applicability of current classification schemes (European Organization for Research and Treatment of Cancer, World Health Organization) based on clinicopathologic features observed in a large group of patients. Blood 2002; 99: 800-5.

  19. Harris NL, Jaffe ES, Stein H, Banks PM, et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 1994; 84: 1361-92.

  20. Harris NL, Jaffe ES, Diebold J, Flandrin G, et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. J Clin Oncol 1999; 17: 3835-49.

  21. Cariappa A, Pillai S. Antigen-dependent B-cell development. Curr Opin Immunol 2002; 14: 241-9.

  22. Rathmell JC, Thompson CB. Pathways of apoptosis in lymphocyte development, homeostasis, and disease. Cell 2002; 109: 97-107.

  23. Besmer E, Gourzi P, Papavasiliou FN. The regulation of somatic hypermutation. Curr Opin Immunol 2004; 16: 241-5.

  24. McHeyzer-Williams MG. B cells as effectors. Curr Opin Immunol 2003; 15: 354-61.

  25. Han S, Zheng B, Takahashi Y, Kelsoe G. Distinctive characteristics of germinal center B cells. Semin Immunol 1997; 9: 255-60.

  26. Hollowood K, Goodlad JR: Germinal centre cell kinetics. J Pathol 1998; 185: 229-33.

  27. Bleul CC, Schultze JL, Springer TA. B lymphocyte chemotaxis regulated in association with microanatomic localization, differentiation state, and B-cell receptor engagement. J Exp Med 1998; 187: 753-62.

  28. McHeyzer-Williams MG, Ahmed R. B-cell memory and the long-lived plasma cell. Curr Opin Immunol 1999; 11: 172-9.

  29. Fagarasan S, Honjo T. T-Independent immune response: new aspects of B-cell biology. Science 2000; 290: 89-92.

  30. Martin F, Kearney JF. Marginal-zone B cells. Nat Rev Immunol 2002; 2: 323-35.

  31. Martin F, Kearney JF. CD21high IgMhigh splenic B cells enriched in the marginal zone: distinct phenotypes and functions. Curr Top Microbiol Immunol 1999; 246: 45-50.

  32. Martin F, Kearney JF. B-cell subsets and the mature preimmune repertoire. Marginal zone and B1 B cells as part of a “natural immune memory”. Immunol Rev 2000; 175: 70-9.

  33. Streilein JW. Circuits and signals of the skin-associated lymphoid tissues (SALT). J Invest Dermatol 1985; 85: 10-3.

  34. Streilein JW. Skin-associated lymphoid tissues (SALT): origins and functions. J Invest Dermatol 1983; 80: 12-6.

  35. Drillenburg P, Pals ST. Cell adhesion receptors in lymphoma dissemination. Blood 2000; 95: 1900-10.

  36. Nihal M, Mikkola D, Wood GS. Detection of clonally restricted immunoglobulin heavy chain gene rearrangements in normal and lesional skin: analysis of the B-cell component of the skin-associated lymphoid tissue and implications for the molecular diagnosis of cutaneous B-cell lymphomas. J Mol Diagn 2000; 2: 5-10.

  37. Bos JD, Zonneveld I, Das PK, Krieg SR, et al. The skin immune system (SIS): distribution and immunophenotype of lymphocyte subpopulations in normal human skin. J Invest Dermatol 1987; 88: 569-73.

  38. Spetz AL, Strominger J, Groh-Spies V. T cell subsets in normal human epidermis. Am J Pathol 1996; 149: 665-74.

  39. Aarts WM, Willemze R, Bende RJ, Meijer CJ, et al. VH gene analysis of primary cutaneous B-cell lymphomas: evidence for ongoing somatic hypermutation and isotype switching. Blood 1998; 92: 3857-64.

  40. Aarts WM, Bende RJ, Steenbergen EJ, Kluin PM, et al. Variable heavy chain gene analysis of follicular lymphomas: correlation between heavy chain isotype expression and somatic mutation load. Blood 2000; 95: 2922-9.

  41. Stamatopoulos K, Belessi C, Papadaki T, Stavroyianni N, et al. Somatic hypermutation patterns in germinal center B-cell malignancies. Hematology 2003; 8: 319-28.

  42. Gellrich S, Rutz S, Golembowski S, Jacobs C, et al. Primary cutaneous follicle center cell lymphomas and large B-cell lymphomas of the leg descend from germinal center cells. A single cell polymerase chain reaction analysis. J Invest Dermatol 2001; 117: 1512-20.

  43. Weller S, Faili A, Garcia C, Braun MC, et al. CD40-CD40L independent Ig gene hypermutation suggests a second B-cell diversification pathway in humans. Proc Natl Acad Sci 2001; 98: 1166-70.

  44. Storz MN, van de RM, Kim YH, Mraz-Gernhard S, et al. Gene expression profiles of cutaneous B-cell lymphoma. J Invest Dermatol 2003; 120: 865-70.

  45. Garatti SA, Roscetti E, Trecca D, Fracchiolla NS, et al. Bcl-1, bcl-2, p53, c-myc, and lyt-10 analysis in cutaneous lymphomas. Recent Results Cancer Res 1995; 139: 249-61.

  46. Gronbaek K, Moller PH, Nedergaard T, Thomsen K, et al. Primary cutaneous B-cell lymphoma: a clinical, histological, phenotypic and genotypic study of 21 cases. Br J Dermatol 2000; 142: 913-23.

  47. Neri A, Fracchiolla NS, Roscetti E, Garatti S, et al. Molecular analysis of cutaneous B- and T-cell lymphomas. Blood 1995; 86: 3160-72.

  48. Gronbaek K, Ralfkiaer E, Kalla J, Skovgaard GL, et al. Infrequent somatic Fas mutations but no evidence of Bcl10 mutations or t(11; 18) in primary cutaneous MALT-type lymphoma. J Pathol 2003; 201: 134-40.

  49. Zoi-Toli O, Meijer CJ, Oudejans JJ, de Vries E, et al. Expression of Fas and Fas ligand in cutaneous B-cell lymphomas. J Pathol 1999; 189: 533-8.

  50. Franco R, Camacho FI, Fernandez-Vazquez A, Algara P, et al. IgV(H) and bcl6 somatic mutation analysis reveals the heterogeneity of cutaneous B-cell lymphoma, and indicates the presence of undisclosed local antigens. Mod Pathol 2004.

  51. Child FJ, Scarisbrick JJ, Calonje E, Orchard G, et al. Inactivation of tumor suppressor genes p15(INK4b) and p16(INK4a) in primary cutaneous B-cell lymphoma. J Invest Dermatol 2002; 118: 941-48.

  52. Stamatopoulos K, Kosmas C, Belessi C, Stavroyianni N, et al. Molecular insights into the immunopathogenesis of follicular lymphoma. Immunol Today 2000; 21: 298-305.

  53. Maes B, Wolf-Peeters C. Marginal zone cell lymphoma--an update on recent advances. Histopathology 2002; 40: 117-26.

  54. Falini B, Mason DY. Proteins encoded by genes involved in chromosomal alterations in lymphoma and leukemia: clinical value of their detection by immunocytochemistry. Blood 2002; 99: 409-26.

  55. Harris NL, Stein H, Coupland SE, Hummel M, et al. New approaches to lymphoma diagnosis. Hematology 2001; 194-220.

  56. Cerroni L, Volkenandt M, Rieger E, Soyer HP, et al. Bcl-2 protein expression and correlation with the interchromosomal 14; 18 translocation in cutaneous lymphomas and pseudolymphomas. J Invest Dermatol 1994; 102: 231-5.

  57. Child FJ, Russell-Jones R, Woolford AJ, Calonje E, et al. Absence of the t(14; 18) chromosomal translocation in primary cutaneous B-cell lymphoma. Br J Dermatol 2001, 144: 735-44.

  58. Hsi ED, Mirza I, Gascoyne RD. Absence of t(14; 18) chromosomal translocation in primary cutaneous B-cell lymphoma. Br J Dermatol 2002; 146: 1110-1.

  59. Sen F, Vega F, Medeiros LJ. Molecular genetic methods in the diagnosis of hematologic neoplasms. Semin Diagn Pathol 2002; 19: 72-93.

  60. Triscott JA, Ritter JH, Swanson PE, Wick MR. Immunoreactivity for bcl-2 protein in cutaneous lymphomas and lymphoid hyperplasias. J Cutan Pathol 1995; 22: 2-10.

  61. Slater DN. Primary cutaneous B-cell lymphoma: how useful is the new European Organisation for Research and Treatment of Cancer Classification? Br J Dermatol 1999; 141: 352-3.

  62. De Leval L, Harris NL, Longtine J, Ferry JA, et al. Cutaneous B-cell lymphomas of follicular and marginal zone types: use of Bcl-6, CD10, Bcl-2, and CD21 in differential diagnosis and classification. Am J Surg Pathol 2001; 25: 732-41.

  63. Akagi T, Motegi M, Tamura A, Suzuki R, et al. A novel gene, MALT1 at 18q21, is involved in t(11; 18) (q21; q21) found in low-grade B-cell lymphoma of mucosa-associated lymphoid tissue. Oncogene 1999; 18: 5785-94.

  64. Wagner M, Rose VA, Linder R, Schulze HJ, et al. Human pathogenic virus-associated pseudolymphomas and lymphomas with primary cutaneous manifestation in humans and animals. Clin Infect Dis 1998; 27: 1299-308.

  65. Garbe C, Stein H, Dienemann D, Orfanos CE. Borrelia burgdorferi-associated cutaneous B-cell lymphoma: clinical and immunohistologic characterization of four cases. J Am Acad Dermatol 1991; 24: 584-90.

  66. Garbe C, Stein H, Gollnick H, Taud W, et al. Cutaneous B-cell lymphoma in chronic Borrelia burgdorferi infection. Report of 2 cases and a review of the literature. Hautarzt 1988; 39: 717-26.

  67. Cerroni L, Zochling N, Putz B, Kerl H. Infection by Borrelia burgdorferi and cutaneous B-cell lymphoma. J Cutan Pathol 1997; 24: 457-61.

  68. Kutting B, Bonsmann G, Metze D, Luger TA, et al. Borrelia burgdorferi-associated primary cutaneous B-cell lymphoma: complete clearing of skin lesions after antibiotic pulse therapy or intralesional injection of interferon alfa-2a. J Am Acad Dermatol 1997; 36: 311-4.

  69. Grange F, Wechsler J, Guillaume JC, Tortel J, et al. Borrelia burgdorferi-associated lymphocytoma cutis simulating a primary cutaneous large B-cell lymphoma. J Am Acad Dermatol 2002; 47: 530-4.

  70. Jelic S, Filipovic-Ljeskovic I. Positive serology for Lyme disease borrelias in primary cutaneous B-cell lymphoma: a study in 22 patients; is it a fortuitous finding? Hematol Oncol 1999; 17: 107-16.

  71. Goodlad JR, Davidson MM, Hollowood K, Batstone P, et al. Borrelia burgdorferi-associated cutaneous marginal zone lymphoma: a clinicopathological study of two cases illustrating the temporal progression of B. burgdorferi-associated B-cell proliferation in the skin. Histopathology 2000; 37: 501-8.

  72. Goodlad JR, Davidson MM, Hollowood K, Ling C, et al. Primary cutaneous B-cell lymphoma and Borrelia burgdorferi infection in patients from the Highlands of Scotland. Am J Surg Pathol 2000; 24: 1279-85.

  73. McKiernan S, Pilkington R, Ramsay B, Walsh A, et al. Primary cutaneous B-cell lymphoma: an association of chronic hepatitis C infection. Eur J Gastroenterol Hepatol 1999; 11: 669-72.

  74. Morand P, Buisson M, Collandre H, Chanzy B, et al. Human herpesvirus 8 and Epstein Barr-virus in a cutaneous B-cell lymphoma and a malignant cell line established from the blood of an AIDS patient. Leuk Lymphoma 1999; 35: 379-87.

  75. Nagore E, Ledesma E, Collado C, Oliver V, et al. Detection of Epstein-Barr virus and human herpesvirus 7 and 8 genomes in primary cutaneous T- and B-cell lymphomas. Br J Dermatol 2000; 143: 320-3.

  76. Wood GS, Kamath NV, Guitart J, Heald P, et al Absence of Borrelia burgdorferi DNA in cutaneous B-cell lymphomas from the United States. J Cutan Pathol 2001, 28: 502-7.

  77. Mackay IR, Rose NR. Autoimmunity and lymphoma: tribulations of B-cells. Nat Immunol 2001; 2: 793-5.

  78. Jubert C, Cosnes A, Clerici T, Gaulard P, et al. Sjogren’s syndrome and cutaneous B-cell lymphoma revealed by anetoderma. Arthritis Rheum 1993; 36: 133-4.

  79. Fam AG, Perez-Ordonez B, Imrie K. Primary cutaneous B-cell lymphoma during methotrexate therapy for rheumatoid arthritis. J Rheumatol 2000; 27: 1546-9.

  80. Landa NG, Zelickson BD, Kurtin PJ, Winkelmann RK. Primary B-cell lymphoma with histologic features of a T-cell neoplasm. J Am Acad Dermatol 1992; 26: 288-92.

  81. Selva-O’Callaghan A, Perez-Lopez J, Solans-Laque R, Lopez-Peig C, et al. Primary cutaneous large B-cell lymphoma of the legs in a patient with primary Sjogren’s syndrome. Clin Exp Rheumatol 2003; 21: 672.

  82. Michaelis S, Kazakov DV, Schmid M, Dummer R, et al. Hepatitis C and G viruses in B-cell lymphomas of the skin. J Cutan Pathol 2003; 30: 369-72.

  83. Mao X, Lillington DM, Child FJ, Russell-Jones R, et al. Comparative Genomic Hybridization Analysis of Primary Cutaneous B-Cell Lymphomas: Identification of Common Genomic Alterations in Disease Pathogenesis. Genes, Chromosomes & Cancer 2002; 35: 144-55.

  84. Cerroni L, Kerl H. Primary cutaneous follicle center cell lymphoma. Leuk. Lymphoma 2001; 42: 891-900.

  85. Berti E, Alessi E, Caputo R, Gianotti R, et al. Reticulohistiocytoma of the dorsum. J Am Acad Dermatol 1988; 19: 259-72.

  86. Alizadeh AA, Eisen MB, Davis RE, Ma C, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000; 403: 503-11.

  87. Rosenwald A, Wright G, Chan WC, Connors JM, et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 2002; 346: 1937-47.

  88. Pan Z, Shen Y, Du C, Zhou G, et al. Two newly characterized germinal center B-cell-associated genes, GCET1 and GCET2, have differential expression in normal and neoplastic B cells. Am J Pathol 2003; 163: 135-44.

  89. Mirza I, Macpherson N, Paproski S, Gascoyne RD, et al. Primary cutaneous follicular lymphoma: an assessment of clinical, histopathologic, immunophenotypic, and molecular features. J Clin Oncol 2002; 20: 647-55.

  90. Pimpinelli N, Santucci M, Mori M, Vallecchi C, et al. Primary cutaneous B-cell lymphoma: a clinically homogeneous entity? J Am Acad Dermatol 1997; 37: 1012-6.

  91. Franco C, Sazunic I, Martinez V, Benavides MI, et al. Primary cutaneous lymphoma: experience with 10 cases. Rev Med Chil 1990; 118: 512-21.

  92. Aguilera NS, Tomaszewski MM, Moad JC, Bauer FA, et al. Cutaneous follicle center lymphoma: a clinicopathologic study of 19 cases. Mod Pathol 2001; 14: 828-35.

  93. Leinweber B, Colli C, Chott A, Kerl H, et al. Differential diagnosis of cutaneous infiltrates of B lymphocytes with follicular growth pattern. Am J Dermatopathol 2004; 26: 4-13.

  94. Bergman R, Kurtin PJ, Gibson LE, Hull PR, et al. Clinicopathologic, immunophenotypic, and molecular characterization of primary cutaneous follicular B-cell lymphoma. Arch Dermatol 2001, 137: 432-9.

  95. Garcia CF, Weiss LM, Warnke RA, Wood GS. Cutaneous follicular lymphoma. Am J Surg Pathol 1986; 10: 454-63.

  96. Goodlad JR, Krajewski AS, Batstone PJ, McKay P, et al. Primary cutaneous follicular lymphoma: a clinicopathologic and molecular study of 16 cases in support of a distinct entity. Am J Surg Pathol 2002; 26: 733-41.

  97. Shaffer AL, Rosenwald A, Staudt LM. Lymphoid malignancies: the dark side of B-cell differentiation. Nat Rev Immunol 2002; 2: 920-32.

  98. Nihal M, Mikkola D, Wood GS. Detection of clonally restricted immunoglobulin heavy chain gene rearrangements in normal and lesional skin: analysis of the B-cell component of the skin-associated lymphoid tissue and implications for the molecular diagnosis of cutaneous B-cell lymphomas. J Mol Diagn 2000; 2: 5-10.

  99. Child FJ, Woolford AJ, Calonje E, Russell-Jones R, et al. Molecular analysis of the immunoglobulin heavy chain gene in the diagnosis of primary cutaneous B-cell lymphoma. J Invest Dermatol 2001, 117: 984-9.

  100. Pimpinelli N, Santucci M. The skin-associated lymphoid tissue-related B-cell lymphomas. Semin Cutan Med Surg 2000; 19: 124-9.

  101. LeBoit PE, McNutt NS, Reed JA, Jacobson M, et al. Primary cutaneous immunocytoma. A B-cell lymphoma that can easily be mistaken for cutaneous lymphoid hyperplasia. Am J Surg Pathol 1994; 18: 969-78.

  102. Duncan LM, LeBoit PE. Are primary cutaneous immunocytoma and marginal zone lymphoma the same disease? Am J Surg Pathol 1997; 21: 1368-72.

  103. Nihal M, Mikkola D, Horvath N, Gilliam AC, et al. Cutaneous lymphoid hyperplasia: a lymphoproliferative continuum with lymphomatous potential. Hum Pathol 2003; 34: 617-22.

  104. Baldassano MF, Bailey EM, Ferry JA, Harris NL, et al. Cutaneous lymphoid hyperplasia and cutaneous marginal zone lymphoma: comparison of morphologic and immunophenotypic features. Am J Surg Pathol 1999; 23: 88-96.

  105. Burg G, Schmid MH, Kung E, Dommann S, et al. Semimalignant (“pseudolymphomatous”) cutaneous B-cell lymphomas. Dermatol Clin 1994; 12: 399-407.

  106. Cerroni L, Goteri G. Differential diagnosis between cutaneous lymphoma and pseudolymphoma. Anal Quant Cytol Histol 2003; 25: 191-8.107. Gilliam AC, Wood GS. Cutaneous lymphoid hyperplasias. Semin Cutan Med Surg 2000; 19: 133-41.

  107. Magro C, Crowson AN, Porcu P, Nuovo GJ. Automated kappa and lambda light chain mRNA expression for the assessment of B-cell clonality in cutaneous B-cell infiltrates: its utility and diagnostic application. J Cutan Pathol 2003; 30: 504-11.

  108. Cerroni L, Signoretti S, Hofler G, Annessi G, et al. Primary cutaneous marginal zone B-cell lymphoma: a recently described entity of low-grade malignant cutaneous B-cell lymphoma. Am J Surg Pathol 1997; 21: 1307-15.

  109. Servitje O, Gallardo F, Estrach T, Pujol RM, et al. Primary cutaneous marginal zone B-cell lymphoma: a clinical, histopathological, immunophenotypic and molecular genetic study of 22 cases. Br J Dermatol 2002; 147: 1147-58.

  110. Sander CA, Kaudewitz P, Kutzner H, Simon M, et al. T-cell-rich B-cell lymphoma presenting in skin. A clinicopathologic analysis of six cases. J Cutan Pathol 1996; 23: 101-8.

  111. Vermeer MH, Geelen FA, van Haselen CW, Voorst Vader PC, et al. Primary cutaneous large B-cell lymphomas of the legs. A distinct type of cutaneous B-cell lymphoma with an intermediate prognosis. Dutch Cutaneous Lymphoma Working Group. Arch Dermatol 1996; 132: 1304-8.

  112. Hoefnagel JJ, Vermeer MH, Jansen PM, Fleuren GJ, et al. Bcl-2, Bcl-6 and CD10 expression in cutaneous B-cell lymphoma: further support for a follicle centre cell origin and differential diagnostic significance. Br J Dermatol 2003; 149: 1183-91.

  113. Grange F, Bekkenk MW, Wechsler J, Meijer CJ, et al. Prognostic factors in primary cutaneous large B-cell lymphomas: a European multicenter study. J Clin Oncol 2001, 19: 3602-10.

  114. Goodlad JR, Krajewski AS, Batstone PJ, McKay P, et al. Primary cutaneous diffuse large B-cell lymphoma: prognostic significance of clinicopathological subtypes. Am J Surg Pathol 2003; 27: 1538-45.

  115. Hembury TA, Lee B, Gascoyne RD, Macpherson N, et al. Primary cutaneous diffuse large B-cell lymphoma: a clinicopathologic study of 15 cases. Am J Clin Pathol 2002; 117: 574-80.

  116. Paulli M, Viglio A, Vivenza D, Capello D, et al. Primary cutaneous large B-cell lymphoma of the leg: histogenetic analysis of a controversial clinicopathologic entity. Hum Pathol 2002; 33: 937-43.

  117. Fernandez-Vazquez A, Rodriguez-Peralto JL, Martinez M, Platon E, et al. Primary Cutaneous Large B-cell Lymphoma. The Relation Between Morphology, Clinical Presentation, Immunohistochemical Markers, and Survival. Am J Surg Pathol 2004; 25: 307-15.

  118. Brogan BL, Zic JA, Kinney MC, Hu JY, et al. Large B-cell lymphoma of the leg: clinical and pathologic characteristics in a North American series. J Am Acad Dermatol 2003; 49: 223-8.

  119. Slater DN. The new World Health Organization classification of haematopoietic and lymphoid tumours: a dermatopathological perspective. Br J Dermatol 2002; 147: 633-9.

  120. Querfeld C, Guitart J, Kuzel TM, Rosen ST. Primary cutaneous lymphomas: a review with current treatment options. Blood Rev 2003; 17: 131-42.

  121. Estrach T. ¿Qué debe saber el dermatólogo “práctico” de la evaluación y tratamiento de los linfomas cutáneos? Piel 2001; 16: 149-55.

  122. Santucci M, Pimpinelli N, Arganini L. Primary cutaneous B-cell lymphoma: a unique type of low-grade lymphoma. Clinicopathologic and immunologic study of 83 cases. Cancer 1991; 67: 2311-26.

  123. Willemze R, Meijer CJ, Sentis HJ, Scheffer E, et al. Primary cutaneous large cell lymphomas of follicular center cell origin. A clinical follow-up study of nineteen patients. J Am Acad Dermatol 1987; 16: 518-26.

  124. Cerroni L, Signoretti S, Hofler G, Annessi G, et al. Primary cutaneous marginal zone B-cell lymphoma: a recently described entity of low-grade malignant cutaneous B-cell lymphoma. Am J Surg Pathol 1997; 21: 1307-15.

  125. Sah A, Barrans SL, Parapia LA, Jack AS, et al. Cutaneous B-cell lymphoma: pathological spectrum and clinical outcome in 51 consecutive patients. Am J Hematol 2004; 75: 1959.

  126. Smith BD, Smith GL, Heald PW, Cooper D, et al. Effectiveness of radiotherapy as initial treatment for cutaneous B-Cell lymphoma. Int J Radiat Oncol Biol Phys 2003; 57: 290.

  127. Smith BD, Glusac EJ, McNiff JM, Smith GL, et al. Primary cutaneous B-cell lymphoma treated with radiotherapy: a comparison of the European Organization for Research and Treatment of Cancer and the WHO classification systems. J Clin Oncol 2004; 22: 634-9.

  128. Eich HT, Eich D, Micke O, Suttzer H, et al. Long-term efficacy, curative potential, and prognostic factors of radiotherapy in primary cutaneous B-cell lymphoma. Int J Radiat Oncol Biol Phys 2003; 55: 899-906.

  129. Rijlaarsdam JU, Toonstra J, Meijer OW, Noordijk EM, et al. Treatment of primary cutaneous B-cell lymphomas of follicle center cell origin: a clinical follow-up study of 55 patients treated with radiotherapy or polychemotherapy. J Clin Oncol 1996; 14: 549-55.

  130. Bekkenk MW, Vermeer MH, Geerts ML, Noordijk EM, et al. Treatment of multifocal primary cutaneous B-cell lymphoma: a clinical follow-up study of 29 patients. J Clin Oncol 1999; 17: 2471-8.

  131. Sarris AH, Braunschweig I, Medeiros LJ, Duvic M, et al. Primary cutaneous non-Hodgkin’s lymphoma of Ann Arbor stage I: preferential cutaneous relapses but high cure rate with doxorubicin-based therapy. J Clin Oncol 2001, 19: 398-405.

  132. Fierro MT, Quaglino P, Savoia P, Verrone A, et al. Systemic polychemotherapy in the treatment of primary cutaneous lymphomas: a clinical follow-up study of 81 patients treated with COP or CHOP. Leuk. Lymphoma 1998; 31: 583-8.

  133. Heinzerling L, Dummer R, Kempf W, Schmid MH, et al. Intralesional therapy with anti-CD20 monoclonal antibody rituximab in primary cutaneous B-cell lymphoma. Arch Dermatol 2000; 136: 374-8.

  134. Heinzerling LM, Urbanek M, Funk JO, Peker S, et al. Reduction of tumor burden and stabilization of disease by systemic therapy with anti-CD20 antibody (rituximab) in patients with primary cutaneous B-cell lymphoma. Cancer 2000; 89: 1835-44.

  135. Sabroe RA, Child FJ, Woolford AJ, Spittle MF, et al. Rituximab in cutaneous B-cell lymphoma: a report of two cases. Br J Dermatol 2000; 143: 157-61.

  136. Fierro MT, Savoia P, Quaglino P, Novelli M, et al. Systemic therapy with cyclophosphamide and anti-CD20 antibody (rituximab) in relapsed primary cutaneous B-cell lymphoma: a report of 7 cases. J Am Acad Dermatol 2003; 49: 281-7.




2020     |     www.medigraphic.com